SV BR 1 GM cancer vaccine ( BriaCell Therapeutics)

Sylvester Comprehensive Cancer Center to Present Groundbreaking Research at ASCO 2025 Annual Meeting

a month ago

• Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types. • Highlighted studies include the ADVANCE clinical trial examining novel multiple myeloma treatments, innovative virtual reality interventions for stem cell transplant patients, and groundbreaking research on alcohol-related cancer mortality in the US. • The extensive research portfolio demonstrates Sylvester's leadership in developing cutting-edge cancer therapies, addressing health disparities, and improving supportive care for diverse patient populations.

BriaPro Develops Novel Antibodies Targeting B7-H3 for Multi-Cancer Immunotherapy Applications

a month ago

• BriaPro Therapeutics, a subsidiary of BriaCell, has developed novel high-affinity antibodies targeting B7-H3, a protein overexpressed in multiple solid tumors while showing limited expression in normal tissues. • The company plans to incorporate these antibodies into its Bria-TILsRx platform, which integrates T cell engagers and immune checkpoint modulators to enhance anti-tumor activity within the tumor microenvironment. • BriaPro has filed provisional US patent applications for this technology and intends to develop it into antibody-drug conjugates, T cell engagers, and targeted immune checkpoint inhibitors for multiple cancer indications.

BriaCell to Present Pivotal Breast Cancer Immunotherapy Data at AACR 2025

2 months ago

• BriaCell Therapeutics will present data from three clinical studies at the 2025 AACR Annual Meeting, including results from its pivotal Phase 3 trial of Bria-IMT in metastatic breast cancer. • The presentations will showcase survival outcomes from a randomized Phase 2 trial of Bria-IMT, an allogeneic whole cell cancer vaccine, potentially offering new treatment options for advanced breast cancer patients. • BriaCell's novel immunotherapy platform Bria-OTS+ will also be featured, highlighting the company's expanding cancer immunotherapy portfolio and innovative approaches to inducing anti-cancer immunity.

DSMB Recommends Continuation of BriaCell's Phase 3 Trial for Metastatic Breast Cancer Immunotherapy

2 months ago

• The independent Data Safety Monitoring Board has completed its second safety review of BriaCell's pivotal Phase 3 study, finding no safety concerns and recommending continuation without modifications. • BriaCell's novel immunotherapy combines Bria-IMT with an immune checkpoint inhibitor for metastatic breast cancer patients, with the trial proceeding under FDA Fast Track Designation. • Company executives highlight the positive safety profile as an encouraging step toward addressing the urgent medical need for effective treatments for metastatic breast cancer patients.

BriaCell Therapeutics to Raise US$5.5 Million in Public Share Offering to Advance Bria-IMT

5 months ago

• BriaCell Therapeutics plans to raise US$5.5 million through a public share offering of common shares and warrants. • The funds will support working capital, general corporate purposes, and the advancement of the company's business objectives. • BriaCell's lead drug, Bria-IMT, is currently in Phase 3 clinical trials for metastatic breast cancer under FDA Fast Track designation. • Recent Data Safety Monitoring Board review recommended continuation of the pivotal Phase 3 trials for Bria-IMT.

BriaCell's Bria-OTS Shows Promise in Metastatic Breast Cancer with Lung Metastasis Resolution

6 months ago

• BriaCell's Bria-OTS, a personalized off-the-shelf immunotherapy, demonstrated resolution of lung metastasis in a metastatic breast cancer patient after just two months of monotherapy. • The Phase 1/2a dose escalation study (NCT06471673) evaluates Bria-OTS in patients with metastatic recurrent breast cancer who have failed at least two prior systemic therapies. • The 78-year-old patient, who had hormone receptor-positive, HER2-negative breast cancer, experienced no toxicity related to the Bria-OTS treatment and remains in the study. • BriaCell plans to expand the evaluation of Bria-OTS, including in combination with immune checkpoint inhibitors, to other cancers like prostate cancer, melanoma, and lung cancer.